145 related articles for article (PubMed ID: 36813855)
1. TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer.
Nair RS; Kumar S; Das S; Singh SK; Srivastava P; Sondarva G; Rao A; Sinha SC; Xiong R; Bloem L; Hoskins K; Thatcher GRJ; Rana B; Rana A
Oncogene; 2023 Mar; 42(14):1132-1143. PubMed ID: 36813855
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.
Viswakarma N; Nair RS; Sondarva G; Das S; Ibrahimi L; Chen Z; Sinha S; Rana B; Rana A
Oncotarget; 2017 May; 8(20):33172-33184. PubMed ID: 28388540
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
4. Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells.
Rangasamy V; Mishra R; Mehrotra S; Sondarva G; Ray RS; Rao A; Chatterjee M; Rana B; Rana A
Cancer Res; 2010 Feb; 70(4):1731-40. PubMed ID: 20145118
[TBL] [Abstract][Full Text] [Related]
5. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
Das S; Sondarva G; Viswakarma N; Nair RS; Osipo C; Tzivion G; Rana B; Rana A
J Biol Chem; 2015 Aug; 290(35):21705-12. PubMed ID: 26152725
[TBL] [Abstract][Full Text] [Related]
6. Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Das S; Nair RS; Mishra R; Sondarva G; Viswakarma N; Abdelkarim H; Gaponenko V; Rana B; Rana A
Oncogene; 2019 May; 38(19):3569-3584. PubMed ID: 30664689
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
8. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
9. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
10. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
11. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
12. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2
Kumar S; Das S; Sun J; Huang Y; Singh SK; Srivastava P; Sondarva G; Nair RS; Viswakarma N; Ganesh BB; Duan L; Maki CG; Hoskins K; Danciu O; Rana B; Li S; Rana A
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2205454119. PubMed ID: 36095190
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
14. Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity.
Kumar S; Singh SK; Viswakarma N; Sondarva G; Nair RS; Sethupathi P; Sinha SC; Emmadi R; Hoskins K; Danciu O; Thatcher GRJ; Rana B; Rana A
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7961-7970. PubMed ID: 32209667
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
16. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
17. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA
J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580
[TBL] [Abstract][Full Text] [Related]
18. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
19. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
[TBL] [Abstract][Full Text] [Related]
20. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]